© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 4, 316-326,
February 19, 2003
© 2003 Oxford University Press
ARTICLE |
Involvement of Toll-Like Receptor 4 Signaling in Interferon-
Production and Antitumor Effect by Streptococcal Agent OK-432
Affiliations of authors: M. Okamoto, T. Oshikawa, T. Tano, G. Ohe, S. Furuichi, H. Nishikawa, S. U. Ahmed, M. Sato, Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan; S. Akashi, K. Miyake, Department of Microbiology and Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; O. Takeuchi, S. Akira, Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan; Y. Moriya, S. Matsubara, Y. Ryoma, M. Saito, Product Research Laboratory, Chugai Pharmaceutical Co., Ltd., Tokyo.
Correspondence to: Mitsunobu Sato, D.D.S., Ph.D., Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, 3-18-15 Kuramoto-cho, Tokushima 7708504, Japan (e-mail: satomitu{at}dent.tokushima-u.ac.jp).
Background: The streptococcal agent OK-432 has been used for immunotherapy of head and neck cancer, among other malignancies, but its mechanism of action is unknown. Because the Toll-like receptor 4 (TLR4)/MD-2 complex is important in enabling the mammalian immune system to recognize bacterial components, we investigated whether expression of the TLR4 and MD-2 genes is associated with OK-432-induced anticancer immunity. Methods: Peripheral blood mononuclear cells (PBMCs) from 28 patients with head and neck cancer were analyzed for TLR4 and MD-2 mRNA expression by reverse transcription–polymerase chain reaction (RT–PCR) analysis. PBMCs were treated in vitro with OK-432 or with OK-PSA (a lipoteichoic-acid-related molecule that is an active component of OK-432), and interferon-gamma (IFN-
) mRNA expression, an immune response measure, was analyzed by RT–PCR. Patient sera collected 24 hours after OK-432 administration were examined for IFN- protein using an enzyme-linked immunosorbent assay. Lewis lung carcinoma-bearing wild-type C57BL/6 and TLR4-deficient mice (four mice per group) received intraperitoneal injections of OK-432, and tumor volumes and sera IFN- levels were measured over time. All statistical tests were two-sided. Results: Twenty patients expressed both TLR4 and MD-2. Expression of TLR4 and MD-2 genes was associated with the in vivo IFN- induction in 19 patients administered OK-432 (Fisher's exact test P<.001). Although both OK-432 and OK-PSA induced IFN- expression from PBMCs in vitro, expression of TLR4 and MD-2 was associated only with IFN- expression induced by OK-PSA (P<.001). In vivo intraperitoneal administration of OK-432 resulted in an increase of IFN- in sera from wild-type mice but not in sera from TLR4-deficient mice. Tumors in wild-type mice treated with OK-432 were statistically significantly smaller than those in mice treated with saline (P = .007). By contrast, in TLR4-deficient mice, there was no difference in tumor volume between the two treatment groups. Conclusions: TLR4 and MD-2 may mediate OK-432-induced anticancer immunity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Zimmer, J. Liu, J. L. Clayton, D. S. Stephens, and J. P. Snyder Paclitaxel Binding to Human and Murine MD-2 J. Biol. Chem., October 10, 2008; 283(41): 27916 - 27926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Hill, F. Errington, L. P. Steele, A. Merrick, R. Morgan, P. J. Selby, N. T. Georgopoulos, D. M. O'Donnell, and A. A. Melcher OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions J. Immunol., September 1, 2008; 181(5): 3108 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okamoto, S. Furuichi, Y. Nishioka, T. Oshikawa, T. Tano, S. U. Ahmed, K. Takeda, S. Akira, Y. Ryoma, Y. Moriya, et al. Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation Cancer Res., August 1, 2004; 64(15): 5461 - 5470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okamoto, G. Oh-e, T. Oshikawa, S. Furuichi, T. Tano, S. U. Ahmed, S. Akashi, K. Miyake, O. Takeuchi, S. Akira, et al. Toll-Like Receptor 4 Mediates the Antitumor Host Response Induced by a 55-Kilodalton Protein Isolated from Aeginetia indica L., a Parasitic Plant Clin. Vaccine Immunol., May 1, 2004; 11(3): 483 - 495. [Abstract] [Full Text] [PDF]
|
|